ECDS has committed ₹780 crore to build a greenfield medtech manufacturing hub in Ujjain, Madhya Pradesh, marking one of the largest single investments in the sector in central India. The announcement, made in early 2026, underscores the company’s confidence in India’s growing domestic demand and export potential for medical devices.

The proposed facility will include: High-precision manufacturing lines for diagnostic imaging (X-ray, ultrasound components), in-vitro diagnostic kits, and molecular testing equipment Production of surgical & interventional devices  orthopaedic implants, stents, catheters, and minimally invasive tools Critical care & hospital consumables ventilators, monitors, syringes, infusion sets, and PPE-grade materials R&D and quality testing labs to support innovation and compliance with CDSCO, ISO 13485, and international standards

The project benefits from Madhya Pradesh’s investor-friendly policies, including land subsidies, power tariff incentives, and single-window clearances under the state’s industrial promotion schemes. It also aligns with the central government’s Production Linked Incentive (PLI) scheme for medical devices and the National Medical Devices Policy 2023, which aim to increase local manufacturing share from ~15% to over 40% by 2030.

Once fully operational, the Ujjain plant is projected to create thousands of direct and indirect jobs, skill local talent in advanced manufacturing, and contribute to reducing the country’s heavy dependence on imported medical devices (currently 70–80% for high-tech categories). ECDS plans phased commissioning, starting with consumables and diagnostics lines in 2027–2028, followed by complex devices.

This investment reflects the accelerating momentum in India’s medtech sector, driven by rising healthcare needs, government support, and export opportunities in emerging markets.